126 related articles for article (PubMed ID: 9598507)
1. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer.
Noldus J; Graefen M; Huland E; Busch C; Hammerer P; Huland H
J Urol; 1998 Jun; 159(6):2004-7; discussion 2007-8. PubMed ID: 9598507
[TBL] [Abstract][Full Text] [Related]
2. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
3. Calculating prostate cancer volume preoperatively: the D'Amico equation and some other observations.
Chan LW; Stamey TA
J Urol; 1998 Jun; 159(6):1998-2003. PubMed ID: 9598506
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
5. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
6. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
7. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Ko JL; Hsieh YS
Jpn J Clin Oncol; 2002 Dec; 32(12):536-42. PubMed ID: 12578903
[TBL] [Abstract][Full Text] [Related]
8. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
10. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
Pannek J; Subong EN; Jones KA; Marschke PL; Epstein JI; Chan DW; Carter HB; Luderer AA; Partin AW
Urology; 1996 Dec; 48(6A Suppl):51-4. PubMed ID: 8973700
[TBL] [Abstract][Full Text] [Related]
11. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
Grossklaus DJ; Shappell SB; Gautam S; Smith JA; Cookson MS
J Urol; 2001 Feb; 165(2):455-8. PubMed ID: 11176395
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
Pettaway CA; Troncoso P; Ramirez EI; Johnston DA; Steelhammer L; Babaian RJ
J Urol; 1998 Aug; 160(2):437-42. PubMed ID: 9679893
[TBL] [Abstract][Full Text] [Related]
15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
17. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer.
Morote J; Trilla E; Esquena S; Serrallach F; Abascal JM; Id H'Mammed Y; de Torres IM
Int J Biol Markers; 2002; 17(4):239-43. PubMed ID: 12521127
[TBL] [Abstract][Full Text] [Related]
18. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract][Full Text] [Related]
19. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
